Livzon Mabpharm to Develop Epirus Biosimilars in China

China's Livzon Mabpharm will collaborate with Epirus Biopharma of Boston to develop up to five biosimilar drugs for the China market. The first product is a Remicade biosimilar, which was recently approved in India. Livzon will develop the drug for China and Taiwan using Epirus' Scale™ manufacturing platform to produce the drug for these two markets. Livzon was a principal investor in Epirus' $36 million funding in April 2014. More details.... Stock Symbol: (NSDQ: EPRS) Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.